Trials / Unknown
UnknownNCT02822157
Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer
Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 160 (actual)
- Sponsor
- Universitaire Ziekenhuizen KU Leuven · Academic / Other
- Sex
- Female
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, open-label, two-arm study in patients with relapsed epithelial ovarian tumors. Patients will be randomized in a 1:1 ratio to receive olaparib or standard chemotherapy with the possibility of crossover at the time of progression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olaparib | |
| DRUG | carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly | physician's choice chemotherapy |
Timeline
- Start date
- 2016-08-01
- Primary completion
- 2021-07-01
- Completion
- 2023-07-01
- First posted
- 2016-07-04
- Last updated
- 2021-01-29
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT02822157. Inclusion in this directory is not an endorsement.